Reata Pharmaceuticals, Inc. - (RETA) News

Reata Pharmaceuticals, Inc. - (RETA): $43.39

2.53 (+6.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RETA News Items

RETA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RETA News Highlights

  • RETA's 30 day story count now stands at 2.
  • Over the past 3 days, the trend for RETA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RETA News From Around the Web

Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript November 8, 2022 Reata Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-2.16, expectations were $-2.18. Operator: Thank you for standing by, and welcome to the Reata Pharmaceuticals Third Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today’s webcast […]

Yahoo | December 31, 2022

15 Most Shorted Stocks Hedge Funds Are Buying

In this article, we will discuss the 15 most shorted stocks hedge funds are buying. You can skip our detailed overview and go directly to the 5 Most Shorted Stocks Hedge Funds Are Buying. The year 2022 has been a dynamic year for financial markets worldwide. The equity markets have come under selling pressure across […]

Yahoo | December 28, 2022

Reata Pharmaceuticals (NASDAQ:RETA) shareholders have endured a 84% loss from investing in the stock three years ago

It is a pleasure to report that the Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is up 60% in the last quarter. But that...

Yahoo | December 22, 2022

Results from Reata Pharmaceuticals Inc. (RETA) show potential

In Tuesday’s session, Reata Pharmaceuticals Inc. (NASDAQ:RETA) marked $35.99 per share, up from $35.80 in the previous session. While Reata Pharmaceuticals Inc. has overperformed by 0.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA rose by 27.26%, with highs and lows ranging from $43.90 to […]

US Post News | December 14, 2022

Reata Pharmaceuticals, Inc. (RETA) Down 1.3% Since Last Earnings Report: Can It Rebound?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2022

Investing in Reata Pharmaceuticals Inc. (RETA) might be a great opportunity, but the stock is a bit overvalued

Reata Pharmaceuticals Inc. (NASDAQ:RETA) closed Monday at $38.20 per share, up from $36.03 a day earlier. While Reata Pharmaceuticals Inc. has overperformed by 6.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA fell by -54.98%, with highs and lows ranging from $95.34 to $18.47, whereas […]

US Post News | November 29, 2022

Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands

Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals shares rose 1.9% to close at $36.03 on Friday. RBC Capital slashed the price target on Edwards Lifesciences Corporation (NYSE: Full story available on Benzinga.com

Benzinga | November 28, 2022

Investing in Reata Pharmaceuticals Inc. (RETA) might be an excellent idea, but the stock is currently overvalued/undervalued

The share price of Reata Pharmaceuticals Inc. (NASDAQ:RETA) rose to $36.71 per share on Wednesday from $35.65. While Reata Pharmaceuticals Inc. has overperformed by 2.97%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA fell by -58.75%, with highs and lows ranging from $95.34 to $18.47, […]

US Post News | November 24, 2022

Reata Pharmaceuticals, Inc.'s stock is down 14%, but insiders still have about US$163k in profit after buying earlier this year

Insiders who purchased Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shares in the past 12 months are unlikely to be...

Yahoo | November 22, 2022

Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD?

During the last session, Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares were 0.85 million, with the beta value of the company hitting 1.19. At the end of the trading day, the stock’s price was $37.94, reflecting an intraday gain of 7.18% or $2.54. The 52-week high for the RETA share is $95.34, that puts it down … Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD? Read More »

Marketing Sentinel | November 19, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5572 seconds.